A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney

Ryoichi Imamura, Yoshitaka Isaka, Ruben M. Sandoval, Naotsugu Ichimaru, Toyofumi Abe, Masayoshi Okumi, Koji Yazawa, Harumi Kitamura, Jyunya Kaimori, Norio Nonomura, Hiromi Rakugi, Bruce Molitoris, Shiro Takahara

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The tissue-protective effects of erythropoietin (EPO) have been extensively investigated, and EPO administration can raise the hemoglobin (Hb) concentration. Recently, we reported that carbamylated erythropoietin (CEPO) protected kidneys from ischemia-reperfusion injury as well as EPO. Methods: To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a tubulointerstitial model rat. We randomized remnant kidney model rats to receive saline, EPO, or CEPO for 8 weeks. Results: CEPO- and EPO-treated rats had improved serum creatinine levels compared with saline-treated remnant kidney model rats, although the Hb level was significantly increased in EPO-treated rats. Two-photon microscopy revealed that EPO/CEPO significantly ameliorated tubular epithelial cell damage assessed by endocytosis. In addition, CEPO or EPO protected endothelial cells with a sustained blood flow rate. EPO or CEPO suppressed the number of TUNEL-positive apoptotic cells with weak αSMA staining. Furthermore, PCR analysis demonstrated that TGF-β and type I collagen expression was attenuated in EPO- or CEPO-treated rats, accompanied by a significant decrease in interstitial fibrosis. Conclusion: We established a long-term therapeutic approach to protect tubulointerstitial injury with CEPO, and thus, the therapeutic value of this approach warrants further attention and preclinical studies.

Original languageEnglish
Pages (from-to)852-862
Number of pages11
JournalClinical and Experimental Nephrology
Volume16
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Erythropoietin
Fibrosis
Kidney
Hemoglobins
carbamylated erythropoietin
In Situ Nick-End Labeling
Therapeutic Uses
Collagen Type I
Endocytosis
Reperfusion Injury
Photons
Microscopy
Creatinine
Endothelial Cells
Epithelial Cells
Staining and Labeling
Polymerase Chain Reaction
Wounds and Injuries
Therapeutics

Keywords

  • Apoptosis
  • Carbamylated erythropoietin
  • Remnant kidney
  • TGF-β

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Imamura, R., Isaka, Y., Sandoval, R. M., Ichimaru, N., Abe, T., Okumi, M., ... Takahara, S. (2012). A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. Clinical and Experimental Nephrology, 16(6), 852-862. https://doi.org/10.1007/s10157-012-0647-x

A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. / Imamura, Ryoichi; Isaka, Yoshitaka; Sandoval, Ruben M.; Ichimaru, Naotsugu; Abe, Toyofumi; Okumi, Masayoshi; Yazawa, Koji; Kitamura, Harumi; Kaimori, Jyunya; Nonomura, Norio; Rakugi, Hiromi; Molitoris, Bruce; Takahara, Shiro.

In: Clinical and Experimental Nephrology, Vol. 16, No. 6, 12.2012, p. 852-862.

Research output: Contribution to journalArticle

Imamura, R, Isaka, Y, Sandoval, RM, Ichimaru, N, Abe, T, Okumi, M, Yazawa, K, Kitamura, H, Kaimori, J, Nonomura, N, Rakugi, H, Molitoris, B & Takahara, S 2012, 'A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney', Clinical and Experimental Nephrology, vol. 16, no. 6, pp. 852-862. https://doi.org/10.1007/s10157-012-0647-x
Imamura, Ryoichi ; Isaka, Yoshitaka ; Sandoval, Ruben M. ; Ichimaru, Naotsugu ; Abe, Toyofumi ; Okumi, Masayoshi ; Yazawa, Koji ; Kitamura, Harumi ; Kaimori, Jyunya ; Nonomura, Norio ; Rakugi, Hiromi ; Molitoris, Bruce ; Takahara, Shiro. / A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. In: Clinical and Experimental Nephrology. 2012 ; Vol. 16, No. 6. pp. 852-862.
@article{c76876f20dbc473cb6cc6aff6b547481,
title = "A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney",
abstract = "Background: The tissue-protective effects of erythropoietin (EPO) have been extensively investigated, and EPO administration can raise the hemoglobin (Hb) concentration. Recently, we reported that carbamylated erythropoietin (CEPO) protected kidneys from ischemia-reperfusion injury as well as EPO. Methods: To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a tubulointerstitial model rat. We randomized remnant kidney model rats to receive saline, EPO, or CEPO for 8 weeks. Results: CEPO- and EPO-treated rats had improved serum creatinine levels compared with saline-treated remnant kidney model rats, although the Hb level was significantly increased in EPO-treated rats. Two-photon microscopy revealed that EPO/CEPO significantly ameliorated tubular epithelial cell damage assessed by endocytosis. In addition, CEPO or EPO protected endothelial cells with a sustained blood flow rate. EPO or CEPO suppressed the number of TUNEL-positive apoptotic cells with weak αSMA staining. Furthermore, PCR analysis demonstrated that TGF-β and type I collagen expression was attenuated in EPO- or CEPO-treated rats, accompanied by a significant decrease in interstitial fibrosis. Conclusion: We established a long-term therapeutic approach to protect tubulointerstitial injury with CEPO, and thus, the therapeutic value of this approach warrants further attention and preclinical studies.",
keywords = "Apoptosis, Carbamylated erythropoietin, Remnant kidney, TGF-β",
author = "Ryoichi Imamura and Yoshitaka Isaka and Sandoval, {Ruben M.} and Naotsugu Ichimaru and Toyofumi Abe and Masayoshi Okumi and Koji Yazawa and Harumi Kitamura and Jyunya Kaimori and Norio Nonomura and Hiromi Rakugi and Bruce Molitoris and Shiro Takahara",
year = "2012",
month = "12",
doi = "10.1007/s10157-012-0647-x",
language = "English",
volume = "16",
pages = "852--862",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney

AU - Imamura, Ryoichi

AU - Isaka, Yoshitaka

AU - Sandoval, Ruben M.

AU - Ichimaru, Naotsugu

AU - Abe, Toyofumi

AU - Okumi, Masayoshi

AU - Yazawa, Koji

AU - Kitamura, Harumi

AU - Kaimori, Jyunya

AU - Nonomura, Norio

AU - Rakugi, Hiromi

AU - Molitoris, Bruce

AU - Takahara, Shiro

PY - 2012/12

Y1 - 2012/12

N2 - Background: The tissue-protective effects of erythropoietin (EPO) have been extensively investigated, and EPO administration can raise the hemoglobin (Hb) concentration. Recently, we reported that carbamylated erythropoietin (CEPO) protected kidneys from ischemia-reperfusion injury as well as EPO. Methods: To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a tubulointerstitial model rat. We randomized remnant kidney model rats to receive saline, EPO, or CEPO for 8 weeks. Results: CEPO- and EPO-treated rats had improved serum creatinine levels compared with saline-treated remnant kidney model rats, although the Hb level was significantly increased in EPO-treated rats. Two-photon microscopy revealed that EPO/CEPO significantly ameliorated tubular epithelial cell damage assessed by endocytosis. In addition, CEPO or EPO protected endothelial cells with a sustained blood flow rate. EPO or CEPO suppressed the number of TUNEL-positive apoptotic cells with weak αSMA staining. Furthermore, PCR analysis demonstrated that TGF-β and type I collagen expression was attenuated in EPO- or CEPO-treated rats, accompanied by a significant decrease in interstitial fibrosis. Conclusion: We established a long-term therapeutic approach to protect tubulointerstitial injury with CEPO, and thus, the therapeutic value of this approach warrants further attention and preclinical studies.

AB - Background: The tissue-protective effects of erythropoietin (EPO) have been extensively investigated, and EPO administration can raise the hemoglobin (Hb) concentration. Recently, we reported that carbamylated erythropoietin (CEPO) protected kidneys from ischemia-reperfusion injury as well as EPO. Methods: To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a tubulointerstitial model rat. We randomized remnant kidney model rats to receive saline, EPO, or CEPO for 8 weeks. Results: CEPO- and EPO-treated rats had improved serum creatinine levels compared with saline-treated remnant kidney model rats, although the Hb level was significantly increased in EPO-treated rats. Two-photon microscopy revealed that EPO/CEPO significantly ameliorated tubular epithelial cell damage assessed by endocytosis. In addition, CEPO or EPO protected endothelial cells with a sustained blood flow rate. EPO or CEPO suppressed the number of TUNEL-positive apoptotic cells with weak αSMA staining. Furthermore, PCR analysis demonstrated that TGF-β and type I collagen expression was attenuated in EPO- or CEPO-treated rats, accompanied by a significant decrease in interstitial fibrosis. Conclusion: We established a long-term therapeutic approach to protect tubulointerstitial injury with CEPO, and thus, the therapeutic value of this approach warrants further attention and preclinical studies.

KW - Apoptosis

KW - Carbamylated erythropoietin

KW - Remnant kidney

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84876293959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876293959&partnerID=8YFLogxK

U2 - 10.1007/s10157-012-0647-x

DO - 10.1007/s10157-012-0647-x

M3 - Article

C2 - 22678524

AN - SCOPUS:84876293959

VL - 16

SP - 852

EP - 862

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 6

ER -